详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword

110| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 预警期刊

作者：

机构： [1]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China [2]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China [3]Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan 030001, China [4]Department of Physiology, Shanxi Medical University, Taiyuan 030001, China

出处：

DOI：

ISSN：

关键词： glioblastoma macrophage microglia immunotherapy targeted therapy

摘要：

Glioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other solid tumors but remain fatigued in GBM patients. Emerging evidence has shown that GBM-associated macrophages (GAMs), comprising brain-resident microglia and bone marrow-derived macrophages, act critically in boosting tumor progression, altering drug resistance, and establishing an immunosuppressive environment. Based on its crucial role, evaluations of the safety and efficacy of GAM-targeted therapy are ongoing, with promising (pre)clinical evidence updated. In this review, we summarized updated literature related to GAM nature, the interplay between GAMs and GBM cells, and GAM-targeted therapeutic strategies.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 4 区生物学

小类 | 3 区生物学

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区生物学

JCR分区：

出版当年[2022]版：

Q2 BIOLOGY

最新[2023]版：

Q1 BIOLOGY

影响因子： 3.2 最新[2023版] 3.1 最新五年平均 3.2 出版当年[2022版] 3.2 出版当年五年平均 3.253 出版前一年[2021版] 3.2 出版后一年[2023版]

第一作者：

第一作者机构： [1]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China [2]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China

共同第一作者：

通讯作者：

通讯机构： [1]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China [2]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy [2]Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma [3]VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment [4]The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma [5]复发/难治外周t细胞淋巴瘤靶向及免疫治疗的研究进展 [6]Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. [7]复发/难治外周t细胞淋巴瘤靶向及免疫治疗的研究进展 [8]Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges [9]Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics. [10]Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.